161 related articles for article (PubMed ID: 17475000)
1. Measures of clinical malaria in field trials of interventions against Plasmodium falciparum.
Smith TA
Malar J; 2007 May; 6():53. PubMed ID: 17475000
[TBL] [Abstract][Full Text] [Related]
2. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL
Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081
[TBL] [Abstract][Full Text] [Related]
3. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.
Horii T; Shirai H; Jie L; Ishii KJ; Palacpac NQ; Tougan T; Hato M; Ohta N; Bobogare A; Arakaki N; Matsumoto Y; Namazue J; Ishikawa T; Ueda S; Takahashi M
Parasitol Int; 2010 Sep; 59(3):380-6. PubMed ID: 20493274
[TBL] [Abstract][Full Text] [Related]
4. Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children.
Høgh B
Scand J Infect Dis Suppl; 1996; 102():1-53. PubMed ID: 9060051
[TBL] [Abstract][Full Text] [Related]
5. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Aide P; Sigauque B; Milman J; Mandomando I; Bassat Q; Guinovart C; Espasa M; Corachan S; Lievens M; Navia MM; Dubois MC; Menendez C; Dubovsky F; Cohen J; Thompson R; Ballou WR
Lancet; 2005 Dec; 366(9502):2012-8. PubMed ID: 16338450
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
[TBL] [Abstract][Full Text] [Related]
7. The development of malaria vaccines: SPf66--what next?
Tanner M; Alonso PL
Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632
[TBL] [Abstract][Full Text] [Related]
8. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction.
Hermsen CC; de Vlas SJ; van Gemert GJ; Telgt DS; Verhage DF; Sauerwein RW
Am J Trop Med Hyg; 2004 Aug; 71(2):196-201. PubMed ID: 15306710
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.
Mahmoudi S; Keshavarz H
Hum Vaccin Immunother; 2017 Sep; 13(9):2098-2101. PubMed ID: 28272979
[TBL] [Abstract][Full Text] [Related]
10. Effect of vitamin A supplementation on morbidity due to Plasmodium falciparum in young children in Papua New Guinea: a randomised trial.
Shankar AH; Genton B; Semba RD; Baisor M; Paino J; Tamja S; Adiguma T; Wu L; Rare L; Tielsch JM; Alpers MP; West KP
Lancet; 1999 Jul; 354(9174):203-9. PubMed ID: 10421302
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.
Bejon P; White MT; Olotu A; Bojang K; Lusingu JP; Salim N; Otsyula NN; Agnandji ST; Asante KP; Owusu-Agyei S; Abdulla S; Ghani AC
Lancet Infect Dis; 2013 Apr; 13(4):319-27. PubMed ID: 23454164
[TBL] [Abstract][Full Text] [Related]
13. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
14. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines.
Penny MA; Maire N; Studer A; Schapira A; Smith TA
PLoS One; 2008 Sep; 3(9):e3193. PubMed ID: 18784833
[TBL] [Abstract][Full Text] [Related]
15. The effect of altitude on parasite density case definitions for malaria in northeastern Tanzania.
Chandler CI; Drakeley CJ; Reyburn H; Carneiro I
Trop Med Int Health; 2006 Aug; 11(8):1178-84. PubMed ID: 16903881
[TBL] [Abstract][Full Text] [Related]
16. [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].
Cohen J; Benns S; Vekemans J; Leach A
Ann Pharm Fr; 2010 Nov; 68(6):370-9. PubMed ID: 21073995
[TBL] [Abstract][Full Text] [Related]
17. [Evaluating malaria attributable morbidity in endemic areas].
Rogier C; Fusaï T; Pradines B; Trape JF
Rev Epidemiol Sante Publique; 2005 Jun; 53(3):299-309. PubMed ID: 16227917
[TBL] [Abstract][Full Text] [Related]
18. [Malaria: recent immunological acquisitions and therapeutic prospects].
Leri O; Perinelli P; Losi T; Mastropasqua M; Peri C; Tubili S
Clin Ter; 1997 Dec; 148(12):655-65. PubMed ID: 9528202
[TBL] [Abstract][Full Text] [Related]
19. The malaria vaccine--status quo 2013.
Heppner DG
Travel Med Infect Dis; 2013; 11(1):2-7. PubMed ID: 23454205
[TBL] [Abstract][Full Text] [Related]
20. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine.
Smith T; Ross A; Maire N; Chitnis N; Studer A; Hardy D; Brooks A; Penny M; Tanner M
PLoS Med; 2012 Jan; 9(1):e1001157. PubMed ID: 22272189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
